National Guideline Clearinghouse | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.

Guideline Title

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.

 

Bibliographic Source(s)

National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 84 p. (Technology appraisal guidance; no. 217).

Guideline Status

This is the current release of the guideline.
This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Aug 1. 84 p. (Technology appraisal guidance; no. 111).

full-text:
National Guideline Clearinghouse Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.